Trial reportSchizophrenia bulletin2015
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
Trial report in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis.Acta neuropsychiatrica · 2019Trial
- The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement.PloS one · 2016Trial
- Psychosocial Interventions, Recovery, and Mediating Mechanisms in Schizophrenia-Spectrum Disorders: A Systematic Review and Meta-Analysis of Longitudinal Studies.Brain sciences · 2026Review
- Hippocampal subfield activity in schizophrenia: Effects of the disease course.Schizophrenia research · 2025Article
- Neurocognition as a major predictor of 8-week response to antipsychotics for drug-naïve first-episode schizophrenia using machine learning.Schizophrenia (Heidelberg, Germany) · 2025Article
- Cognitive Inflexibility Predicts Negative Symptoms Severity in Patients with First-Episode Psychosis: A 1-Year Follow-Up Study.Brain sciences · 2024Article
- Correlations between Negative Symptoms and Cognitive Deficits in Individuals at First Psychotic Episode or at High Risk of Psychosis: A Systematic Review.Journal of clinical medicine · 2023Review
- Neurocognitive and social cognitive impairments in remission and symptomatic states of early-onset schizophrenia spectrum disorders.European child & adolescent psychiatry · 2023Article
- Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study.BMJ open · 2022Article
- A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages.Psychiatry research · 2022Review
- The difference of social cognitive and neurocognitive performance between patients with schizophrenia at different stages and influencing factors.Schizophrenia research. Cognition · 2021Article
- Long acting aripiprazole influences cognitive functions in recent onset schizophrenia.Psychopharmacology · 2021Article
- Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study.BMC psychiatry · 2021Article
- Verbal memory measurement towards digital perspectives in first-episode psychosis: A review.Schizophrenia research. Cognition · 2020Review
- Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum HDL levels in a cohort of first episode psychosis patients.European archives of psychiatry and clinical neuroscience · 2020Article
- Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
- Neuropsychological functioning in early and chronic stages of schizophrenia and psychotic bipolar disorder.Schizophrenia research · 2019Article
- Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment.Nature communications · 2018Article
- Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.Schizophrenia bulletin · 2018Article
- Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia.Frontiers in psychiatry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
First-episode schizophrenia (FES) spectrum disorders are associated with pronounced cognitive dysfunction across all domains. However, less is known about the course of cognitive functioning, following the first presentation of psychosis, and the relationship of cognition to clinical course during initial treatment. The present longitudinal study examined the magnitude of neurocognitive impairment, using the MATRICS Consensus Cognitive Battery, in patients experiencing their first episode of psychosis at baseline and after 12 weeks of randomized antipsychotic treatment with either aripiprazole or risperidone. At baseline, FES patients evidenced marked impairments in cognitive functioning. Notably, performance on the mazes task of planning and reasoning significantly predicted the likelihood of meeting stringent criteria for positive symptom remission during the first 12 weeks of the trial. Performance on indices of general cognitive function, working memory, and verbal learning improved over time, but these improvements were mediated by improvements in both positive and negative symptoms. We did not detect any differential effects of antipsychotic medication assignment (aripiprazole vs risperidone) on cognitive functioning. Our results suggest that a brief paper-and-pencil measure reflecting planning/reasoning abilities may index responsivity to antipsychotic medication. However, improvements in cognitive functioning over time were related to clinical symptom improvement, reflecting "pseudospecificity."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.